Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes : Findings from the Ovarian Cancer Association Consortium

Purpose—Chemotherapy resistance remains a major challenge in the treatment of ovarian cancer. We hypothesize that germline polymorphisms might be associated with clinical outcome. Correspondence to: Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston 4006, Australia, Ph: + 61 7 3362 0390, georgia.trench@qimrberghofer.edu. au. *These authors contributed equally Financial Disclosure AUS studies (Australian Ovarian Cancer Study and the Australian Cancer Study) were funded by Army Medical Research and Materiel Command (DAMD17–01–1–0729), National Health & Medical Research Council of Australia, Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; National Health and Medical Research Council of Australia (199600 and 400281). The grant numbers for AOCS Cancer Council funding are as followsMulti-State Application Numbers 191, 211 and 182. The Bavarian study (BAV) was supported by ELAN Funds of the University of Erlangen-Nuremberg. The Belgian study (BEL) was funded by Nationaal Kankerplan. The Diseases of the Ovary and their Evaluation (DOV) study was funded by National Institutes of Health R01-CA112523 and R01-CA87538. The German Ovarian Cancer Study (GER) was supported by the German Federal Ministry of Education and Research of Germany, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ). The Hawaii Ovarian Cancer Study (HAW) was supported by R01 CA 058598. The Hormones and Ovarian Cancer Prediction study (HOP) was supported by US National Cancer Institute: K07CA80668; R01CA095023; P50-CA159981; R01-CA126841; US Army Medical Research and Materiel Command: DAMD17–02–1– 0669; NIH/National Center for Research Resources/General Clinical Research Center grant MO1RR000056. The Women’s Cancer Program (LAX) was supported by the American Cancer Society Early Detection Professorship (120950-SIOP-06–258–06-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124. The Mayo Clinic Case-Only Ovarian Cancer Study (MAC) was funded by the National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393). The Mayo Clinic Ovarian Cancer Case-Control Study (MAY) was supported by National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation. The MALOVA study (MAL) was funded by The National Cancer Institute (grant RO1-CA 61107), The Danish Cancer Society (grant (94– 222–52) and The Mermaid I project. The North Carolina Ovarian Cancer Study (NCO) National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17–02–1–0666). The New England-based Case-Control Study of Ovarian Cancer (NEC) was supported by NIH grants R01 CA 054419–10 and P50 CA105009, and Department of Defense CDMRP grant W81XWH-10–1–0280. The New Jersey Ovarian Cancer Study (NJO) was funded by the National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey. The Oregon study (ORE) was funded by the Sherie Hildreth Ovarian Cancer Research Fund and the OHSU Foundation. The Polish Ovarian Cancer Case Control Study (POL) was funded by Intramural Research Program of the National Cancer Institute. The SEARCH study (SEA) was supported by Cancer Research UK (C490/A8339, C490/A10119, C490/A10124 and C490/A16561) and UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The Scottish Randomised Trial in Ovarian Cancer (SRO) was funded by Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589). The Gynaecological Oncology Biobank at Westmead (WMH) is a member of the Australasian Biospecimen Network-Oncology group, funded by the Australian National Health and Medical Research Council Enabling Grants ID 310670 & ID 628903 and the Cancer Institute NSW Grant ID 12/RIG/1-17. The United Kingdom Ovarian cancer Population Study (UKO) was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UK Familial Ovarian Cancer Registry (UKR) Cancer Research UK (C490/A6187); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. The Los Angeles County Case-Control Studies of Ovarian Cancer-3 (USC) P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00–01389V-20170, 2II0200). The Warsaw Ovarian Cancer Study (WOC) Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27), The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. There are no conflicts of interest to disclose HHS Public Access Author manuscript Clin Cancer Res. Author manuscript; available in PMC 2016 June 01. Published in final edited form as: Clin Cancer Res. 2015 December 1; 21(23): 5264–5276. doi:10.1158/1078-0432.CCR-15-0632. A uhor M anscript